Dosing and uses of Baciguent (bacitracin topical)
Adult dosage forms and strengths
ointment
- 500unit/g
Dermal Infections (Superficial)
Apply ointment qDay-q8hr
Pediatric dosage forms and strengths
ointment
- 500unit/g
Dermal Infections (Superficial)
Apply ointment qDay-q8hr
Baciguent (bacitracin topical) adverse (side) effects
Frequency not defined
Rash
Itching
Pain
Hypersensitivity reaction (rare)
Warnings
Contraindications
Hypersensitivity, atopic patients
Cautions
Preparations should not be used for longer than 1 wk unless directed by a physician
Pregnancy and lactation
Pregnancy category: C
Lactation: Excretion in milk unknown; use with caution
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Baciguent (bacitracin topical)
Mechanism of action
Inhibits bacterial cell wall synthesis, by preventing the incorporation of mucopeptides into the growing cell walL
Absorption
Not substantially absorbed from intact or denuded skin, wounds, or mucous membranes
